Overview

Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients.

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

At present, there is some clinical data for different functional response to beta-blockers associated with beta-adrenergic receptor polymorphisms. But there has been no data reported, about the incidence of beta-adrenergic receptor polymorphism and association with beta-adrenergic receptor polymorphism and response to beta-blocker therapy in Korean heart failure (HF) subjects. This single-arm, open-label, multicentric study is designed with the purpose of analyzing the association between genetic polymorphism of beta-adrenergic receptor and the effects of beta-blocker (bisoprolol) in Korean HF subjects.

Phase:

Phase 4

Details

Lead Sponsor:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Collaborator:

Merck Ltd.

Treatments:

Adrenergic Agents
Bisoprolol